

## **BAB VII**

### **DAFTAR PUSTAKA**

1. Abbo A., Carmeli Y, Navon-Venezia S, Seigman-Igra Y, Schwaber M.J. Impact of Multidrug-Resistant *Acinetobacter baumanii* on Clinical Outcomes. European Journal of Clinical Microbiology and Infectious Diseases 2007; 26: 793-800.
2. Cerqueira GM, Peleg AY. Insights into *Acinetobacter baumannii* pathogenicity. IUBMB Life. 2011; 63: 1055-1060.
3. Etebu E, Arikepar I. Antibiotics: Classification and mechanisms of action with emphasis on molecular perspectives. International Journal of Applied Microbiology and Biotechnology Research. 2016; 4: 90-101.
4. Howard A, Donoghue MO, Feeney A, Sleator RD. *Acinetobacter baumanii*: An emerging opportunistic pathogen. Virulence 2012; 3(3): 243-250.
5. Freire MP, Garcia DO, Garcia CP, Bueno MFC, Camargo CH, et al. Bloodstream infection caused by extensively drug-resistant *Acinetobacter baumannii* in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. European Society of Clinical Microbiology and Infectious Diseases 2016; 22(4): 352-358.
6. Hamdiyati R, Pinatih KJP, Fatmawati NND. Pola Mikroba Pasien yang Dirawat di Intensive Care Unit RSUP Sanglah Denpasar serta Kepekaannya Terhadap Antibiotik pada Agustus – Oktober 2013. 2013; 10-13.
7. Katarnida SS, Karyanti MR, Oman DM, Katar Y. Pola Sensitifitas Bakteri dan Penggunaan Antibiotik. Sari Pediatri 2013; 15(2): 122-126.
8. Kurniawati AFS, Satyabakti P, Arbianti N. Perbedaan Risiko *Multidrug Resistance Organisms* (MDROS) menurut Faktor Risiko dan Kepatuhan Hand Hygiene. Jurnal Berkala Epidemiologi 2015; 3(3): 277-289.
9. Lemos EV, Hoz FPDL, Einarson TR, McGhan WF, Quewedо E, et al. Carbapenem resistance and mortality in patients with *Acinetobacter baumannii* infection: systematic review and meta-analysis. Clinical Microbiology and Infection 2014; 20: 416-423.

10. Maragakis LL, Perl TM. *Acinetobacter baumannii*: Epidemiology, Antimicrobial Resistance and Treatment Options. *Antimicrobial Resistance* 2012; 46: 1254-1263.
11. Mathai AS, Oberoi A, Madhavan S, Kaur P. *Acinetobacter* infections in a tertiary level intensive care unit in northern India: Epidemiology, clinical profiles and outcomes. *Journal of Infection and Public Health* 2012; 5: 145-152.
12. Menteri Kesehatan Republik Indonesia. Program Pengendalian Resistensi Antimikroba di Rumah Sakit. 2015.
13. Nurmala, Virgiandhy IGN, Andriani, Liana DF. Resistensi dan Sensitivitas Bakteri terhadap Antibiotik di RSU dr. Soedarso Pontianak Tahun 2011-2013. *eJournal Kedokteran Indonesia* 2015; 3(1): 21-28.
14. Nutman A, Glick R, Temkin E, Hoshen M, Edgar R, et al. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant *Acinetobacter baumannii* bacteraemia. *European Society of Clinical Microbiology and Infectious Diseases* 2014; 20: 1028-1034.
15. Rahman V, Anggraini D, Fauziah D. Pola Resistensi *Acinetobacter baumannii* yang diisolasi di *Intensive Care Unit* (ICU) RSUD Arifin Achmad Provinsi Riau Periode 1 Januari hingga 31 Desember 2014. *Jom FK* 2015; 2(2): 1-8.
16. Singh BR. Antibiotics: Introduction to Classification. Research Gate 2015.
17. Sosa ADJ, Byarugaba DK, Cuevas CFA, Hsueh PR, Kariuki S, et al. Antimicrobial Resistance in Developing Countries. Springer 2010.
18. Villoria AMG, Garduno VV. Antibiotic-Resistant *Acinetobacter baumannii* Increasing Success Remains a Challenge as a Nosocomial Pathogen. *Journal of Pathogens* 2016; 1-10.
19. William ES, Lee TB, Montgomery OG, Marx J, Olmsted RN. Recommended Practices for Surveillance: Association for Professionals in Infection Control and Epidemiology (APIC), Inc. *American Journal of Infection Control* 2012; 35(7): 427-440.